Clinical Trial Update: Safety and Efficacy of CIS43LS Anti-malaria mAb in Mali [Phase 2]

View source ↗

Summary

Phase 2 trial in Mali evaluating the safety and efficacy of CIS43LS, an anti-malaria monoclonal antibody, with results posted in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malaria
• Plasmodium Falciparum Malaria

Drugs mentioned

• CIS43LS monoclonal antibody (CIS43LS)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Plasmodium Falciparum Infection, Malaria | Phase 2 | Status: COMPLETED | Results posted: 2024-05-02